Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

Maria E. Suarez-Almazor; Xerxes Pundole; Noha Abdel-Wahab; Douglas B. Johnson; Dipti Gupta; Ilya Glezerman; Tim Cooksley; Ronald Anderson; Ada Blidner; Jennifer Choi; Michael Dougan; Pamela Ginex; Monica Girotra; Vickie R. Shannon; Bernardo L. Rapoport

doi:10.1007/s00520-020-05710-8

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

Maria E. Suarez-Almazor, Xerxes Pundole, Noha Abdel-Wahab, Douglas B. Johnson, Dipti Gupta, Ilya Glezerman, Tim Cooksley, Ronald Anderson, Ada Blidner, Jennifer Choi, Michael Dougan, Pamela Ginex, Monica Girotra, Vickie R. Shannon, Bernardo L. Rapoport

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.

Original language	English (US)
Pages (from-to)	6159-6173
Number of pages	15
Journal	Supportive Care in Cancer
Volume	28
Issue number	12
DOIs	https://doi.org/10.1007/s00520-020-05710-8
State	Published - Dec 2020

Keywords

Arthralgia
Arthritis
Cardiomyopathy
Corticosteroids
Immunomodulation agents
Myocarditis
Myositis
Other immunosuppressive agents
Polymyalgia

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s00520-020-05710-8

Fingerprint

Dive into the research topics of 'Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors'. Together they form a unique fingerprint.

Cite this

Suarez-Almazor, M. E., Pundole, X., Abdel-Wahab, N., Johnson, D. B., Gupta, D., Glezerman, I., Cooksley, T., Anderson, R., Blidner, A., Choi, J., Dougan, M., Ginex, P., Girotra, M., Shannon, V. R., & Rapoport, B. L. (2020). Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Supportive Care in Cancer, 28(12), 6159-6173. https://doi.org/10.1007/s00520-020-05710-8

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. / Suarez-Almazor, Maria E.; Pundole, Xerxes; Abdel-Wahab, Noha et al.
In: Supportive Care in Cancer, Vol. 28, No. 12, 12.2020, p. 6159-6173.

Research output: Contribution to journal › Article › peer-review

Suarez-Almazor, ME, Pundole, X, Abdel-Wahab, N, Johnson, DB, Gupta, D, Glezerman, I, Cooksley, T, Anderson, R, Blidner, A, Choi, J, Dougan, M, Ginex, P, Girotra, M, Shannon, VR & Rapoport, BL 2020, 'Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors', Supportive Care in Cancer, vol. 28, no. 12, pp. 6159-6173. https://doi.org/10.1007/s00520-020-05710-8

Suarez-Almazor ME, Pundole X, Abdel-Wahab N, Johnson DB, Gupta D, Glezerman I et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Supportive Care in Cancer. 2020 Dec;28(12):6159-6173. doi: 10.1007/s00520-020-05710-8

@article{907fc1294a864de38ed3151bf1db2b6a,

title = "Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors",

abstract = "Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.",

keywords = "Arthralgia, Arthritis, Cardiomyopathy, Corticosteroids, Immunomodulation agents, Myocarditis, Myositis, Other immunosuppressive agents, Polymyalgia",

author = "Suarez-Almazor, {Maria E.} and Xerxes Pundole and Noha Abdel-Wahab and Johnson, {Douglas B.} and Dipti Gupta and Ilya Glezerman and Tim Cooksley and Ronald Anderson and Ada Blidner and Jennifer Choi and Michael Dougan and Pamela Ginex and Monica Girotra and Shannon, {Vickie R.} and Rapoport, {Bernardo L.}",

note = "Publisher Copyright: {\textcopyright} 2020, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2020",

month = dec,

doi = "10.1007/s00520-020-05710-8",

language = "English (US)",

volume = "28",

pages = "6159--6173",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "12",

}

TY - JOUR

T1 - Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

AU - Suarez-Almazor, Maria E.

AU - Pundole, Xerxes

AU - Abdel-Wahab, Noha

AU - Johnson, Douglas B.

AU - Gupta, Dipti

AU - Glezerman, Ilya

AU - Cooksley, Tim

AU - Anderson, Ronald

AU - Blidner, Ada

AU - Choi, Jennifer

AU - Dougan, Michael

AU - Ginex, Pamela

AU - Girotra, Monica

AU - Shannon, Vickie R.

AU - Rapoport, Bernardo L.

PY - 2020/12

Y1 - 2020/12

N2 - Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.

AB - Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.

KW - Arthralgia

KW - Arthritis

KW - Cardiomyopathy

KW - Corticosteroids

KW - Immunomodulation agents

KW - Myocarditis

KW - Myositis

KW - Other immunosuppressive agents

KW - Polymyalgia

UR - http://www.scopus.com/inward/record.url?scp=85089896593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089896593&partnerID=8YFLogxK

U2 - 10.1007/s00520-020-05710-8

DO - 10.1007/s00520-020-05710-8

M3 - Article

C2 - 32856212

AN - SCOPUS:85089896593

SN - 0941-4355

VL - 28

SP - 6159

EP - 6173

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 12

ER -

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this